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MaBACKGROUND Although running is a popular leisure-time physical activity, little is known about the long-term effects
of running on mortality. The dose-response relations between running, as well as the change in running behaviors over
time, and mortality remain uncertain.
OBJECTIVES We examined the associations of running with all-cause and cardiovascular mortality risks in 55,137
adults, 18 to 100 years of age (mean age 44 years).
METHODS Running was assessed on a medical history questionnaire by leisure-time activity.
RESULTS During a mean follow-up of 15 years, 3,413 all-cause and 1,217 cardiovascular deaths occurred. Approximately
24% of adults participated in running in this population. Compared with nonrunners, runners had 30% and 45% lower
adjusted risks of all-cause and cardiovascular mortality, respectively, with a 3-year life expectancy beneﬁt. In dose-
response analyses, the mortality beneﬁts in runners were similar across quintiles of running time, distance, frequency,
amount, and speed, compared with nonrunners. Weekly running even <51 min, <6 miles, 1 to 2 times, <506 metabolic
equivalent-minutes, or <6 miles/h was sufﬁcient to reduce risk of mortality, compared with not running. In the analyses
of change in running behaviors and mortality, persistent runners had the most signiﬁcant beneﬁts, with 29% and 50%
lower risks of all-cause and cardiovascular mortality, respectively, compared with never-runners.
CONCLUSIONS Running, even 5 to 10 min/day and at slow speeds <6 miles/h, is associated with markedly reduced
risks of death from all causes and cardiovascular disease. This study may motivate healthy but sedentary individuals to
begin and continue running for substantial and attainable mortality beneﬁts. (J Am Coll Cardiol 2014;64:472–81)
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ABB R E V I A T I O N S
AND ACRONYMS
BMI = body mass index
CVD = cardiovascular disease
MET = metabolic equivalent
PAF = population attributable
fraction
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473However, compared with the compelling evi-
dence on moderate-intensity activity and health (4), it
is unclear whether there are health beneﬁts to vigorous-
intensity activity, such as running, for <75 min per week.
This study was conducted to investigate whether
leisure-time running is associated with all-cause and
cardiovascular disease (CVD) mortality risks, whether
there is a dose-response relation between running and
mortality, and whether different patterns of change in
running behaviors are associated with mortality.
METHODS
STUDY POPULATION. The Aerobics Center Longitu-
dinal Study is a prospective, observational cohort
study designed to examine the effects of physical
activity and ﬁtness on various health outcomes.
Participants are self-referred or are referred by their
employers or physicians for periodic preventive med-
ical examinations at the Cooper Clinic in Dallas,
Texas. This cohort is primarily college-educated, non-
Hispanic white adults from middle to upper socioeco-
nomic strata (5). The current study participants were
men and women 18 to 100 years of age (mean age 44
years) at baseline who received at least 1 extensive
medical examination between 1974 and 2002. Among
60,603 participants, we excluded 3,294 individuals
reporting myocardial infarction (MI), stroke, or cancer
at baseline and 2,172 individuals with <1 year of mor-
tality follow-up to minimize potential bias due to
serious undetected underlying diseases on mortality.
The ﬁnal sample included 55,137 individuals (26%
women) for analysis of all-cause mortality and 52,941
individuals for analysis of CVD mortality, after 2,196
individuals who died from causes other than CVDwere
excluded. The Cooper Institute Institutional Review
Board reviewed and approved the study annually. All
participants gave written informed consent for the
examinations and follow-up study.
ASSESSMENT OF RUNNING. Running or jogging
activity during the past 3 months was assessed at
baseline by the physical activity questionnaire,
including 4 questions about duration, distance, fre-
quency, and speed as part of the medical examination.
For calculation of the total weekly running time, the
average duration of running was multiplied by the
frequency. For calculation of the total amount of
running, the metabolic equivalent (MET) value for a
given speed was multiplied by the weekly running
time (6). Participants were classiﬁed into 6 groups:
nonrunners and 5 quintiles of weekly running
time (minutes), distance (miles), frequency (times),
amount (MET-minutes), and speed (miles/h) in run-
ners. For complete analyses of running characteristicsand mortality, we deﬁned runners as
those who reported all 4 detailed running
questions and nonrunners as those who did
not report any running questions. We also
examined the associations between change in
running behaviors andmortality in a subgroup
of 20,647 participants from the overall sample
of 60,603 who received at least 2 medical ex-
aminations between 1974 and 2002 and were free from
MI, stroke, or cancer at both examinations. We deﬁned
4 categories of change in running behaviors using the
baseline and last follow-up examination: “remained
nonrunners” were nonrunners at both examinations,
“became nonrunners” were runners only at the base-
line examination, “became runners” were runners
only at the last examination, and “remained runners”
were runners at both examinations. Total amount of
other physical activities except running (cycling,
swimming, walking, basketball, racquet sports, aero-
bic dance, and other sports-related activities) was
classiﬁed into 3 groups: 0, 1 to 499, and $500 MET-
minutes per week based on the Physical Activity
Guidelines (3). To reduce confounding bias in the
association between running and mortality, the total
amount of other physical activities except runningwas
adjusted in all multivariable regression models. Our
physical activity assessment has been described else-
where (7) and was formerly validated and shown to
correlate to measured cardiorespiratory ﬁtness and
physiological variables (5,8).
CLINICAL EXAMINATION. Physicians conducted
comprehensive examinations. Resting blood pressure
was recorded using the standard auscultation method.
Blood glucose and cholesterol were analyzed using
automated bioassays after $12 h of overnight fast. Body
mass index (BMI) was calculated from measured weight
and height (kg/m2). Cardiorespiratory ﬁtness was
assessed using a maximal treadmill exercise test (9).
Standardizedmedical questionnaires were used to assess
health behaviors (smoking, alcohol consumption, and
leisure-time physical activity), physician-diagnosed
medical conditions, and parental history of CVD.
MORTALITY SURVEILLANCE. Participants were fol-
lowed for mortality from the baseline examination
through the date of death for decedents or December
31, 2003, for survivors using the National Death In-
dex. For the analysis of change in running behaviors
and mortality, we followed for mortality from the
last follow-up examination through the date of
death or 2003. Death from CVD was deﬁned by the
International Classiﬁcation of Diseases-9th edition
(ICD-9) codes 390-449.9 and ICD-10 Revision codes
I00-I78.
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474STATISTICAL ANALYSIS. Multivariable Cox propor-
tional hazard models were used to estimate hazard
ratios (HRs) and 95% CI of mortality across running
categories. Population attributable fractions (PAFs)
and survival differences for running and other
mortality predictors determined by the baseline
assessment were estimated, as described by Bruzzi
et al. (10) and using the risk advancement period
approach (11). We tested effect modiﬁcation by sex
on the associations between running and mortality
using interaction terms in the regressions and by
comparing risk estimates in the sex-stratiﬁed ana-
lyses. Based on no signiﬁcant interactions observed,
pooled analyses were performed. The proportional
hazard assumptions were satisﬁed by comparing
the log-log survival plots. SAS software (SAS Insti-
tute, Inc., Cary, North Carolina) was used for all
analyses, and 2-sided p values <0.05 were deemed
signiﬁcant.TABLE 1 Population Characteristics by Quintile of Weekly Running Ti
Characteristic
Nonrunners
(0)
1
(<51)
Female 29.1 12.4
Age, yrs 45  11 40  9
Body mass index, kg/m2* 26.3  4.7 25.2  3
<25.0 42.3 49.9
25.0–29.9 40.6 42.6
$30.0 17.1 7.5
Smoking status
Never 53.9 58.1
Former 27.3 29.0
Current 18.8 12.9
Heavy alcohol drinking† 17.2 19.3
Total amount of other physical activities
except running (MET-min/week)‡
0 59.0 61.6
1–499 16.6 11.2
$500 24.4 27.2
Systolic blood pressure, mm Hg 120  15 118  1
Diastolic blood pressure, mm Hg 81  10 79  9
Hypertension§ 31.6 22.1
Fasting glucose, mg/dl 99.7  19.1 97.1  11
Diabetesk 6.2 3.4
Total cholesterol, mg/dl 208.5  40.8 200.3  3
Hypercholesterolemia¶ 29.3 20.8
Abnormal electrocardiogram# 8.7 4.9
Parental cardiovascular disease 27.6 23.0
Cardiorespiratory ﬁtness (maximal METs)** 10.2  2.2 12.5  1
Values are mean  SD or %. *Calculated as the weight in kg divided by the square of th
respectively. ‡Total physical activity levels from other leisure-time activities except run
physician diagnosis. kDeﬁned as fasting glucose$126 mg/dl, current therapy with insulin,
of physician diagnosis. #Deﬁned as abnormal resting or exercise electrocardiogram, inc
**Estimated from the ﬁnal treadmill speed and grade during the maximal exercise test i
MET ¼ metabolic equivalent.RESULTS
There were 3,413 all-cause deaths and 1,217 CVD
deaths during the mean (interquartile range) follow-
up of 14.7 (6.5 to 21.7) years and 14.6 (6.3 to 21.8)
years, respectively. At baseline, runners were more
likely to be men, younger, and leaner; were less likely
to smoke and participate in other types of physical
activities; had lower prevalence of chronic diseases;
and had higher cardiorespiratory ﬁtness levels
(Table 1).
Compared with nonrunners, runners had 30%
and 45% lower risks of all-cause and CVD mortality,
respectively, after adjustment for potential con-
founders (Fig. 1). These associations were consistent
regardless of sex, age, BMI, health conditions,
smoking status, and alcohol consumption. We esti-
mated PAFs for running and other mortality pre-
dictors, such as smoking, overweight/obesity, andme
Quintile of Running Time (min/week)
2
(51–80)
3
(81–119)
4
(120–175)
5
(‡176)
15.5 14.4 15.9 17.9
41  9 42  9 42  9 43  9
.2 25.0  3.2 24.8  3.0 24.6  3.1 23.9  2.9
53.1 55.4 58.1 67.9
40.3 39.2 36.4 28.8
6.6 5.4 5.5 3.3
54.8 54.1 55.5 54.5
32.8 35.4 36.1 38.5
12.4 10.5 8.4 7.0
18.2 19.2 18.4 17.9
69.1 72.4 71.8 72.1
9.9 8.6 8.3 6.6
21.0 19.0 19.9 21.3
3 119  14 119  14 120  14 120  14
79  10 79  9 79  9 79  9
22.9 24.0 24.2 23.9
.8 97.5  13.0 97.3  11.8 97.2  11.6 97.0  10.6
3.3 2.8 3.0 2.9
8.4 201.3  38.9 201.7  38.1 200.3  38.4 199.2  37.8
21.1 21.5 21.5 19.6
4.8 5.1 4.5 5.8
23.5 26.2 27.5 27.4
.9 12.8  2.0 13.2  2.1 13.6  2.2 14.6  2.6
e height in m. †Deﬁned as >14 and >7 alcohol drinks per week for men and women,
ning. §Deﬁned as systolic or diastolic blood pressure $140/90 mm Hg or history of
or history of physician diagnosis. ¶Deﬁned as total cholesterol$240 mg/dl or history
luding rhythm and conduction disturbances and ischemic ST-T wave abnormalities.
n a subsample of 50,995 participants.
Subgroup
Subgroup
Hazard Ratio (95%  CI) of All-Cause Mortality
Hazard Ratio (95%  CI) of Cardiovascular Mortality
Men
Women
Age <50 yr
Age ≥50 yr
BMI <25 kg/m2
BMI ≥25 kg/m2
Healthy individuals
Unhealthy individuals
Nonsmokers
Smokers
Nonheavy alcohol drinkers
Heavy alcohol drinkers
Excluded first 3 years of deaths
Excluded BMI <18.5 kg/m2
Excluded abnormal ECG
Overall
Men
Women
Age <50 yr
Age ≥50 yr
BMI <25 kg/m2
BMI ≥25 kg/m2
Healthy individuals
Unhealthy individuals
Nonsmokers
Smokers
Nonheavy alcohol drinkers
Heavy alcohol drinkers
Excluded first 3 years of deaths
Excluded BMI <18.5 kg/m2
Excluded abnormal ECG
Overall
0.71 (0.64-0.78)
0.72 (0.62-0.82)
0.71 (0.63-0.81)
0.73 (0.64-0.83)
0.74 (0.65-0.84)
0.82 (0.70-0.95)
0.69 (0.61-0.77)
0.77 (0.70-0.85)
0.51 (0.39-0.65)
0.71 (0.64-0.79)
0.66 (0.54-0.81)
0.71 (0.65-0.78)
0.70 (0.64-0.77)
0.70 (0.64-0.78)
0.70 (0.64-0.77)
0.61 (0.45-0.85)
0.1 0.2 0.4 0.8
0.1 0.2 0.4 0.8
0.56 (0.47-0.67)
0.32 (0.16-0.64)
0.51  (0.39-0.68)
0.60 (0.49-0.74)
0.57 (0.45-0.72)
0.70 (0.50-0.99)
0.58 (0.48-0.70)
0.62 (0.52-0.75)
0.34 (0.21-0.55)
0.55 (0.46-0.67)
0.56 (0.38-0.81)
0.56 (0.47-0.66)
0.55 (0.46-0.65)
0.53 (0.43-0.64)
0.55 (0.46-0.65)
0.64 (0.50-0.83)
Running Better Nonrunning Better 
Running Better Nonrunning Better 
FIGURE 1 HRs of All-Cause and Cardiovascular Mortality by Subgroup
The reference group for all analyses includes nonrunners. All hazard ratios (HRs) were
adjusted for baseline age (years), sex (not in sex-stratiﬁed analyses), examination year,
smoking status (never, former, or current [not in smoking-stratiﬁed analyses]), alcohol
consumption (heavy drinker or not [not in alcohol drinking-stratiﬁed analyses]), other
physical activities except running (0, 1 to 499, or $500 MET-min/week), and parental
cardiovascular disease (yes or no). Unhealthy was deﬁned as the presence of 1 or more of
the following health conditions: abnormal electrocardiogram (ECG), hypertension,
diabetes, or hypercholesterolemia. Heavy alcohol drinking was deﬁned as >14 and >7
drinks per week for men and women, respectively. BMI ¼ body mass index.
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475chronic diseases. Not running was almost as im-
portant as hypertension, accounting for 16% of
all-cause and 25% of CVD mortality (Table 2). Also,
nonrunners had 3 years’ lower life expectancy com-
pared with runners after adjustment for other
mortality predictors.
In the dose-response analyses (Table 3), runners
across all 5 quintiles of weekly running time, even
the lowest quintile of <51 min/week had lower risks
of all-cause and CVD mortality compared with non-
runners. However, these mortality beneﬁts were
similar between lower and higher doses of weekly
running time. In fact, among runners (after non-
runners were excluded in the analyses), there were
no signiﬁcant differences in HRs of all-cause and CVD
mortality across quintiles of weekly running time
(all p values >0.10). In additional analyses using
weekly running times of <60, 60 to 119, 120 to 179,
and $180 min, we found similar trends with the cor-
responding HRs of 0.73 (95% CI: 0.61 to 0.86), 0.65
(95% CI: 0.56 to 0.75), 0.71 (95% CI: 0.59 to 0.86), and
0.76 (95% CI: 0.63 to 0.92) for all-cause mortality and
0.46 (95% CI: 0.33 to 0.65), 0.56 (95% CI: 0.43 to 0.73),
0.54 (95% CI: 0.38 to 0.77), and 0.65 (95% CI: 0.46
to 0.92) for CVD mortality, respectively, compared
with nonrunners after adjustment for confounders
included in model 2. All analyses were adjusted
for total physical activity levels achieved by other
leisure-time activities besides running (model 2).
When we excluded individuals who reported parti-
cipating in other activities besides running (39%),
similar associations between weekly running time
and mortality were found (all p values <0.05).
Furthermore, we adjusted for possible intermediate
variables, such as BMI and medical conditions, on
the causal pathway between running and mortality
(model 3). The associations were attenuated but
remained signiﬁcant at the lower levels of running
time. However, to avoid overadjustment for inter-
mediate variables, we did not adjust for those inter-
mediate variables in the models for other analyses.
Runners across all quintiles of other running char-
acteristics had lower risks of all-cause mortality
compared with nonrunners (Fig. 2). Even the lowest
quintiles of weekly running distance (<6 miles), fre-
quency (1 to 2 times), amount (<506 MET-minutes),
and speed (<6 miles/h) had signiﬁcantly lower risks of
all-causemortality comparedwith not running. Similar
trends were observed with the risk of CVD mortality.
Among 20,647 individuals who received 2 med-
ical examinations over a mean (interquartile range)
interval of 5.9 (1.5 to 8.5) years, 65% of participants
remained nonrunners, 14% stopped running, 8%started running, and 13% continued running, indi-
cating that the more consistent group was the inac-
tive nonrunners. Compared with never-runners
(nonrunners at both examinations), runners at 1 or
both examinations were more likely to have lower
mortality risk (Fig. 3). Persistent runners over an
TABLE 2 HRs, PAFs, and Estimated Decreased Life Expectancy by Running and Other Mortality Predictors
Mortality Predictor
All–Cause Mortality* Cardiovascular Mortality*
HR (95% CI) PAF, %†
Decreased Life
Expectancy, yrs‡ HR (95% CI) PAF, %†
Decreased Life
Expectancy, yrs‡
Nonrunner 1.24 (1.13–1.37) 16 3.0 1.40 (1.18–1.66) 25 4.1
Current smoker 1.67 (1.54–1.80) 11 7.0 1.69 (1.49–1.92) 12 6.3
Overweight or obesity 1.16 (1.08–1.25) 8 2.0 1.43 (1.26–1.63) 20 4.4
Parental CVD 1.20 (1.12–1.29) 7 2.5 1.38 (1.23–1.54) 13 3.9
Abnormal ECG 1.55 (1.42–1.70) 7 6.0 2.43 (2.14–2.77) 17 10.7
Hypertension 1.46 (1.36–1.57) 15 5.2 1.94 (1.72–2.18) 28 8.0
Diabetes 1.36 (1.23–1.51) 3 4.2 1.53 (1.31–1.79) 6 5.1
Hypercholesterolemia 1.06 (0.98–1.13) 2 0.7 1.32 (1.18–1.48) 10 3.4
*Hazard ratios (HRs), population attributable fractions (PAFs), and decreased life expectancy were adjusted for baseline age (years), sex, examination year, and all other
mortality predictors in the table. The reference category for each HR and PAF analysis includes individuals who did not have the particular mortality predictor. †PAF was
computed as Pc(1 – 1/HRadj), for which Pc is the prevalence of the mortality predictor among mortality cases and HRadj is the multivariable HR for mortality associated with the
speciﬁed mortality predictor. Pc (ordered as listed in the table) was 83.7, 28.4, 59.6, 40.9, 19.0, 47.4, 12.6, and 33.9 for all-cause mortality and 86.7, 28.4, 66.7, 46.2, 29.2,
58.0, 16.6, and 41.6 for cardiovascular mortality. ‡Decreased life expectancy was compared by beta coefﬁcients for mortality associated with each year of age, with the beta
coefﬁcient difference in mortality for each mortality predictor using the multivariable Cox proportional hazards model.
CVD ¼ cardiovascular disease; ECG ¼ electrocardiogram.
TABLE 3 HRs of All-
Group
All-cause mortality
No. of participants
No. of deaths
Person-yrs of follow
Death rate*
Adjusted HR (95% C
Model 1†
Model 2‡
Model 3§
Cardiovascular mortalit
No. of participants
No. of deaths
Person-yrs of follow
Death rate*
Adjusted HR (95% C
Model 1†
Model 2‡
Model 3§
*Death rate per 10,000 pe
smoking status (never, form
§Model 3 was adjusted for
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476average of 5.9 years, however, had the most signi-
ﬁcant mortality beneﬁt, with 29% and 50% lower
risk of all-cause and CVD mortality, respectively.
DISCUSSION
There were 3 major ﬁndings from this study (Central
Illustration). First, runners had consistently lowerCause and Cardiovascular Mortality by Quintile of Weekly Running Time
Nonrunners
(0)
Quint
1
(<51)
2
(51–80)
42,121 2,710 2,584
2,857 110 116
-up 602,752 41,653 42,197
45.9 31.7 29.7
I)
1.00 0.69 (0.57–0.83) 0.65 (0.54–0.78)
1.00 0.70 (0.58–0.85) 0.67 (0.55–0.80)
1.00 0.80 (0.66–0.97) 0.76 (0.63–0.91)
y
40,319 2,628 2,501
1,055 28 33
-up 575,352 40,497 40,766
17.8 8.0 9.0
I)
1.00 0.45 (0.31–0.66) 0.50 (0.36–0.71)
1.00 0.45 (0.31–0.66) 0.52 (0.37–0.73)
1.00 0.59 (0.40–0.86) 0.67 (0.47–0.95)
rson-years adjusted for baseline age, sex, and examination year. †Model 1 was adjusted for ba
er, or current), alcohol consumption (heavy drinker or not), other physical activities except
model 2 plus body mass index (kg/m2) and presence or absence of abnormal electrocardiorisk of all-cause and CVD mortality compared with
nonrunners. Second, running even at lower doses
or slower speeds was associated with signiﬁcant
mortality beneﬁts. Third, persistent running over
time was more strongly associated with mortality
reduction.
An earlier study found a 39% lower risk of all-cause
mortality in 538 runners who were $50 years of ageile of Running Time, min/week
3
(81–119)
4
(120–175)
5
(‡176)
2,505 2,647 2,570
103 112 115
41,082 40,473 40,426
29.8 31.5 33.8
0.65 (0.53–0.79) 0.69 (0.57–0.83) 0.74 (0.61–0.89)
0.67 (0.55–0.82) 0.71 (0.58–0.86) 0.77 (0.63–0.92)
0.78 (0.64–0.95) 0.84 (0.69–1.02) 0.89 (0.74–1.07)
2,435 2,567 2,491
33 32 36
39,983 39,275 39,233
10.3 9.1 11.6
0.58 (0.41–0.82) 0.51 (0.36–0.72) 0.65 (0.46–0.91)
0.60 (0.42–0.84) 0.53 (0.37–0.75) 0.67 (0.48–0.93)
0.82 (0.58–1.16) 0.78 (0.54–1.11) 0.86 (0.62–1.21)
seline age (years), sex, and examination year. ‡Model 2 was adjusted for model 1 plus
running (0, 1 to 499, or $500 MET-minutes per week), and parental CVD (yes or no).
gram, hypertension, diabetes, and hypercholesterolemia.
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477from the Runners Association database compared
with 423 matched nonrunners from the Lipid
Research Clinics database after adjustment for base-
line age, sex, and functional ability (12). In our sub-
sample of runners $50 years of age, we found 29%
lower mortality risk, compared with nonrunners. The
somewhat greater mortality beneﬁts of running in
the earlier study may be because runners from a
running club were more likely to be health conscious,
and physical activities other than running were not
adjusted for in the analyses.
Recently, the Copenhagen City Heart Study found
similar mortality beneﬁts in 1,878 joggers, compared
with nonjoggers after adjustment for a similar set of
confounders used in our analyses (13). In their dose-
response analysis, they observed a U-shaped relation
between jogging time and mortality. Compared with0.8 1.00
0
0 1-2 3 4 5
0 <506
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FIGURE 2 HRs of All-Cause and Cardiovascular Mortality by Runnin
Participants were classiﬁed into 6 groups: nonrunners and 5 quintiles of
were adjusted for baseline age (years), sex, examination year, smoking st
physical activities except running (0, 1 to 499, or $500 MET-min/week)
and HRs are shown next to the bars. MET ¼ metabolic equivalent.no jogging, weekly jogging <150 min was associated
withmortality reduction; however,$150minofweekly
joggingdid not showsigniﬁcantmortality beneﬁts, due
to the small numbers of deaths and wide conﬁdence
intervals in that category. In our current study of more
than 13,000 runners, we used quintiles of weekly
running time to have an equal number of participants
across different doses of running. We found a lower
mortality risk in running >150 min/week. However,
mortality beneﬁts were slightly less at the highest
quintile of weekly running time of $176 min/week.
Several studies have suggested slightly lower or
no mortality beneﬁt at higher doses of vigorous-
intensity activities. The Harvard Alumni Study
reported a slightly higher death rate in individuals
who participated in vigorous sports for $180
min/week compared with <180 min/week (14).1.00
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FIGURE 3 HRs of All-Cause and Cardiovascular Mortality by Change in
Running Behaviors
Model 1 was adjusted for baseline age (years), sex, examination year, and interval between
the baseline and last examinations (years). Model 2 was adjusted for model 1 plus baseline
smoking status (never, former, or current), alcohol consumption (heavy drinker or not),
other physical activities except running (0, 1 to 499, or $500 MET-min/week), and
parental cardiovascular disease (CVD; yes or no). The number of participants (deaths) in
remained nonrunners, became nonrunners, became runners, and remained runners were
13,522 (1,013), 2,847 (141), 1,578 (131), and 2,700 (113) for all-cause mortality and 12,885
(376), 2,753 (47), 1,485 (38), and 2,616 (29) for cardiovascular mortality, respectively. The
bars indicate 95% CI, and HRs are shown next to the bars.
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478A large study of 416,175 adults found no additional
mortality beneﬁts for >50 min/day of vigorous-
intensity activities (15). Recent studies have
proposed that excessive endurance sports may
potentially induce adverse cardiovascular effects,
such as arrhythmias and myocardial damage (16–19).
In contrast, there are studies showing a linear dose-
response relation between running and CVD risk,
with more beneﬁts at higher doses of running (20,21).
Thus, future studies are needed on this dose-response
issue about whether there is an optimumupper limit of
vigorous-intensity activities, beyondwhich additional
activity provides no further mortality beneﬁts.
Another short report from the Copenhagen City
Heart Study suggested a reduced mortality risk in 96
persistent male joggers (22). Our study now suggeststhat even less persistent runners (runners at 1 of the 2
examinations over 5.9 years of interval) appeared to
have some mortality beneﬁts compared with never-
runners. However, persistent runners had the most
mortality beneﬁt.
Current physical activity guidelines recommend
a minimum of 75 min/week of vigorous-intensity
aerobic activity such as running for health beneﬁts
(2,3). However, we found mortality beneﬁts with
even <75 min/week of running. In additional ana-
lyses, we found that a minimum of 30 to 59 min/week
of running (5 to 10 min/day) was associated with
lower risks of all-cause (HR: 0.72; 95% CI: 0.59 to
0.88) and CVD mortality (HR: 0.42; 95% CI: 0.28
to 0.63), compared with no running. Several large
studies have also suggested mortality beneﬁts for
<75 min/week of vigorous-intensity aerobic activities
(15,21,23,24). This ﬁnding has clinical and public
health importance. Because time is one of the stron-
gest barriers to participate in physical activity, this
study may motivate more people to start running
and continue to run as an attainable health goal
for mortality beneﬁts. Compared with moderate-
intensity activity, vigorous-intensity activity, such
as running, may be a better option for time efﬁciency,
producing similar, if not greater, mortality beneﬁts in
5 to 10 min/day in many healthy but sedentary
individuals who may ﬁnd 15 to 20 min/day of
moderate-intensity activity too time consuming.
However, for the majority of the population who
are inactive and may not want to participate in
running as a daily routine, a progressive transitional
phase (for example, starting with walking) may be
useful to reduce injury risk. In the context of pop-
ulation mortality burden, we found that if all non-
runners became runners in this population, 16%
of all-cause deaths and 25% of CVD deaths would
be prevented, based on the estimation of PAFs.
Because several studies reported acute MI or sud-
den cardiac death during running races, we exam-
ined the long-term effects of running on coronary
heart disease mortality and sudden cardiac death.
Compared with nonrunners, runners had 45% lower
risk of coronary heart disease mortality (HR: 0.55;
95% CI: 0.44 to 0.69), after adjustment for potential
confounders. In addition, the sudden cardiac death
rate was approximately half in runners compared
with nonrunners (1.5 vs. 0.7 per 10,000 person-
years). Furthermore, runners had a 40% lower risk
of stroke mortality (HR: 0.60; 95% CI: 0.39 to 0.92),
compared with nonrunners after adjustment for
confounders.
Several randomized controlled trials have reported
that vigorous-intensity aerobic activities improved
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CENTRAL ILLUSTRATION Leisure-Time Running Reduced All-Cause and Cardiovascular Mortality Risk
Hazard ratios (HRs) of all-cause and cardiovascular mortality by running characteristic (weekly running time, distance, frequency, total amount, and speed).
Participants were classiﬁed into 6 groups: nonrunners (reference group) and 5 quintiles of each running characteristic. All HRs were adjusted for baseline
age (years), sex, examination year, smoking status (never, former, or current), alcohol consumption (heavy drinker or not), other physical activities except
running (0, 1 to 499, or $500 MET-minutes/week), and parental history of cardiovascular disease (yes or no). All p values for HRs across running char-
acteristics were <0.05 for all-cause and cardiovascular mortality except for running frequency of $6 times/week (p ¼ 0.11) and speed of <6.0 miles/h
(p ¼ 0.10) for cardiovascular mortality. Abbreviation as in Figure 2.
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479blood pressure, insulin sensitivity, and blood lipid
proﬁle (25–27). There is also convincing observational
evidence of the beneﬁts of running in preventing
chronic diseases, including coronary heart disease,
stroke, hypertension, diabetes, and hypercholester-
olemia (20,21,28). Cardiorespiratory ﬁtness is a strong
morbidity and mortality predictor (9,29,30), as a
possible link between running and mortality (12). We
found that runners had approximately 30% higher
cardiorespiratory ﬁtness than nonrunners, and there
was a linear increase of cardiorespiratory ﬁtness
with increasing running time (p < 0.001) at base-
line (Fig. 4). Every 30 min of additional weekly
running time was associated with 0.5 MET highercardiorespiratory ﬁtness after accounting for age and
sex (p < 0.001). We found no mortality beneﬁts of
running after further adjustment for cardiorespira-
tory ﬁtness, as we have previously observed in total
leisure-time physical activity and mortality (7).
Therefore, it is possible that the mortality beneﬁts
of running may be explained by improved cardiore-
spiratory ﬁtness. However, running is a behavior
and cardiorespiratory ﬁtness is a physiological attri-
bute, which also is affected by other factors such as
genotype. Thus, the current ﬁndings of no additional
mortality beneﬁts at the higher doses of running
compared with lower doses of running may be related
to other factors besides cardiorespiratory ﬁtness.
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FIGURE 4 Baseline Cardiorespiratory Fitness by Weekly Running Time
Cardiorespiratory ﬁtness was estimated from the ﬁnal treadmill speed and grade during the maximal exercise test in a subsample of 50,995
participants. All p values for linear trend across weekly running time were <0.001 after adjustment for age and sex (not in sex-stratiﬁed
analyses). Abbreviation as in Figure 2.
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480Strengths of this study include the very large
sample size across a wide age range, extensive mor-
tality follow-up, comprehensive analyses, and control
of potential confounding factors including other
nonrunning activities. In addition, we used various
running characteristics to investigate the associa-
tions of both baseline and change in running with
mortality.
STUDY LIMITATIONS. Our cohort consisted primar-
ily of well-educated white adults from middle to
upper socioeconomic strata, which may limit the
generalizability of the ﬁndings. However, the po-
tential for confounding by race/ethnicity, educa-
tion, and income may be reduced in this population.
Physiological characteristics of our cohort are
similar to those of other representative population
samples (5). Another limitation is the use of self-
reported running during the past 3 months, which
is longer than conventional physical activity ques-
tionnaires that include the previous 1 week or 1
month. Although running during the past 3 months
could be more representative than running during
the previous week or month, it may also increase
the inaccuracy of self-report of running due to
recall bias. People tend to overreport their leisure-
time physical activities because it is a socially
desirable behavior (31). However, this overreporting
bias would likely induce an underestimation of
the true mortality beneﬁts of running toward thenull hypothesis. Runners are healthier than non-
runners in this population, with lower prevalence of
chronic diseases at baseline (Table 1). It is possible
that healthy people may run more, which could
lead to reverse causality. However, we found
consistent mortality beneﬁts in runners in both
healthy and unhealthy individuals (Fig. 1). Also, we
observed mortality beneﬁts after additional adjust-
ment for medical conditions (Table 3). Another
potential limitation is the lack of adequate dietary
information.
CONCLUSIONS
We found consistent long-term mortality beneﬁts of
leisure-time running. This study underlined that
running even at relatively low doses (5 to 10 min/
day), below the current minimum guidelines of
vigorous-intensity aerobic activity, was sufﬁcient for
substantial mortality beneﬁts.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Leisure-
time running, even at low intensity or pace, reduces all-
cause and cardiovascular mortality independently of sex,
age, body mass index, health behavior, and medical condi-
tions. Reduction inmortality is related to continued running
activity over time, and running is as important as such other
prognostic variables like smoking, obesity, or hypertension.
COMPETENCY IN INTERPERSONAL AND COMMU-
NICATION SKILLS: Healthcare providers should explain
to patients the signiﬁcant mortality beneﬁts of running
even as little as 5 to 10 min daily. Try to motivate patients
to start running and to continue running as an attainable
health goal.
TRANSLATIONAL OUTLOOK: Further research is
needed to determine whether there is an upper limit to
the amount of vigorous physical activity, beyond which
additional exercise provides no further mortality
reduction.
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